论文部分内容阅读
目的:研究脂蛋白相关磷脂酶A2(Lp-PLA2)联合改良版ABCD2评分与轻型缺血性卒中早期神经功能恶化(END)的相关性。方法:本研究共收集148例急性轻型缺血性卒中患者为研究对象,应用改良版ABCD2评分进行风险分层,ELISA法检测患者血浆Lp-PLA2水平。结果:END和无END 2组轻型缺血性卒中患者进行比较,END组Lp-PLA2水平显著升高(P<0.05)。Lp-PLA2与改良版ABCD2评分显著相关(P<0.05)。多因素Cox回归分析结果显示ABCD2评分(≥4分)、大动脉狭窄(≥75%)及Lp-PLA2(>200 ng/m L)是轻型脑缺血卒中END复合终点事件的预测因素(P<0.05)。结论:Lp-PLA2联合改良版ABCD2评分可提高轻型缺血性卒中END事件的风险预测能力。
AIM: To investigate the association between lipoprotein-associated phospholipase A2 (Lp-PLA2) and modified ABCD2 score and early neurological dysfunction (END) in light ischemic stroke. METHODS: A total of 148 patients with acute ischemic stroke were enrolled in this study. Risk stratification was performed using a modified version of ABCD2, and plasma levels of Lp-PLA2 were measured by ELISA. Results: Lp-PLA2 levels in END group were significantly higher than those in non-END 2 group (P <0.05). Lp-PLA2 was significantly associated with the modified ABCD2 score (P <0.05). Multivariate Cox regression analysis showed that ABCD2 score (≥4 points), stenosis of aorta (≥75%) and Lp-PLA2 (> 200 ng / m L) were predictors of END composite end point in patients with mild-type cerebral ischemic stroke (P < 0.05). CONCLUSIONS: Lp-PLA2 in conjunction with the modified ABCD2 score improves the risk-prediction ability of END events in light-ischemic stroke.